New GLI Executive Vice President of Scientific and Regulatory Affairs
W: (609) 924-7207
M: (732) 766-3563
Global Liver Institute Names Dr. Brian Harvey Executive Vice President of Scientific and Regulatory Affairs
Washington, DC (June 15, 2015) -- The Global Liver Institute (GLI) is pleased to announce it appointed Dr. Brian Harvey, former Vice President of U.S. Regulatory Strategy at Pfizer, Inc., to the position of Executive Vice President of Scientific and Regulatory Affairs.
Dr. Harvey will support and guide GLI on scientific, medical and regulatory matters, supporting its mission to promote innovation, encourage collaboration between diverse partners and scale optimal approaches to eradicate liver diseases. Dr. Harvey has served on GLI’s board since its’ founding in 2014.
"We are thrilled to have Brian join our leadership team as EVP of Scientific and Regulatory Affairs," said Donna Cryer, Founder and President of GLI. “Brian not only has a wealth of medical knowledge and experience as a practicing physician, but, having worked within both U.S. Food and Drug Administration and at several leading pharmaceutical companies, he brings to GLI extensive industry experience that will help us identify opportunities to transform the field of liver disease.”
“Yet beyond his professional experience, I know first-hand that Brian is an extraordinary human being,” explained Mrs. Cryer. “Our history together dates back over 20 years when he was a Gastroenterology Fellow at Johns Hopkins Hospital and I was his patient.”
Dr. Harvey most recently served as Vice President of U.S. Regulatory Strategy at Pfizer, covering pharmaceuticals and biologics across all therapeutic areas., as well as regulatory liaison for global medical devices. Prior to joining Pfizer, Dr. Harvey was VP of U.S. Regulatory Policy for Sanofi-Aventis. Dr. Harvey also worked at the U.S. Food & Drug Administration, in the medical devices (CDRH), biologics (CBER) and drugs (CDER) centers, including as director of FDA’s Division of Gastroenterology Products. In 2000-2001, he represented the FDA as an American Political Science Association (APSA) Congressional Fellow, where he worked on health and scientific issues in the U.S. Senate.
“I’m proud to join Donna and her team as they apply their new formula for advocacy and collaboration to tackle the complex public health issues surrounding liver disease,” said Dr. Harvey. “Liver disease affects over 30 million people in this country alone, and I believe GLI’s approach to advocacy can not only raise awareness of liver disease, but rapidly develop and disseminate solutions that can improve the lives of patients and their families.”
Dr. Harvey graduated with honors from Middlebury College in Vermont. He earned his Ph.D. in biochemistry, followed by his M.D. degree at the University of Connecticut. He conducted post-doctoral research at Harvard Medical School, followed by his internal medicine internship and residency at Boston’s Beth Israel Hospital. He then completed a three-year gastroenterology fellowship at the Johns Hopkins Hospital in Baltimore, MD, prior to joining the FDA.
The Global Liver Institute (GLI) was founded by Mrs. Cryer in 2014 to facilitate collaboration among patient advocates, policymakers, regulators, health systems and payers to help co-design and accelerate the adoption of solutions that can improve liver health and lead to better treatment of liver diseases.
Founded in 2014, The Global Liver Institute is redefining traditional advocy to defeat liver disease. Through the creation of high-level, collaborative partnerships with public, private and academic institutions, GLI drives the development of innovating solutions to complex problem that can be scaled to impact patients, clinicians or other stakeholder groups. To address the low level of awareness and stigma associated with liver disease, GLI recruits high-profile celebrities and media organizations to spread knowledge and understanding. By bringing together diverse stakeholders, promoting collaboration and scaling novel approached, GLI hopes to improve the effectiveness of the liver community -- and one day eradicate liver disease.